Taken together, this is the first clinical study investigating and comparing CAR19/22 T-cell cocktail and its combination with ASCT for effectiveness in TP53-disrupted r/r B-cell lymphoma. Here, TP53 is linked to B-cell non-Hodgkin lymphoma.